Zoetis Inc
ZTS
NYSE
Pharmaceuticals
$75.02
USD
-1.66 (-2.16%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $30.19B
Volume 3.9M
Revenue
$9.52B
TTM
+1.5%
YoY
Gross Margin
72%
TTM
+0.3%
YoY
Net Income
$2.62B
TTM
+0.6%
YoY
Operating Cash Flow
$2.89B
TTM
-3.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2,474.0 | 2,400.0 | 2,387.0 | 2,262.0 | 2,468.0 |
YoY Growth | +4.8% | +0.5% | +3.0% | +2.9% | -0.2% |
Cost of Revenue | 664.0 | 683.0 | 712.0 | 641.0 | 673.0 |
Gross Profit | 1,810.0 | 1,717.0 | 1,675.0 | 1,621.0 | 1,795.0 |
Selling, General & Administrative | 614.0 | 579.0 | 619.0 | 588.0 | 592.0 |
Other Operating Expenses | 30.0 | 4.0 | 17.0 | 22.0 | 77.0 |
Total Operating Expenses | 843.0 | 785.0 | 866.0 | 821.0 | 873.0 |
Operating Income | 967.0 | 932.0 | 809.0 | 800.0 | 922.0 |
EBITDA | 1,121.0 | 1,060.0 | 947.0 | 941.0 | 1,118.0 |
Other Income / Expense | -2.0 | 13.0 | 9.0 | 20.0 | 5.0 |
Total Other Income / Expense | -55.0 | -45.0 | -48.0 | -42.0 | -56.0 |
Income Before Income Taxes | 912.0 | 887.0 | 761.0 | 758.0 | 866.0 |
Income Taxes | 186.0 | 166.0 | 158.0 | 157.0 | 175.0 |
Net Income | 726.0 | 721.0 | 603.0 | 601.0 | 691.0 |
Consolidated Net Income / Loss | 726.0 | 721.0 | 603.0 | 601.0 | 691.0 |
Net Income Attributable to Common Shareholders | 726.0 | 721.0 | 603.0 | 601.0 | 691.0 |
Basic EPS | $1.63 | $1.63 | $1.38 | $1.42 | $1.65 |
Diluted EPS | $1.63 | $1.63 | $1.37 | $1.42 | $1.65 |
Basic Shares Outstanding | 445.1M | 442.9M | 438.2M | 422.1M | 417.6M |
Diluted Shares Outstanding | 445.5M | 443.2M | 438.6M | 422.4M | 417.7M |